血液透析人群丙型肝炎微消除路径更新
该综述指出全球透析设施内丙型肝炎病毒(HCV)传播持续存在,世界卫生组织2030年透析人群微消除目标难以按期实现。指南、法规与经济因素交织构成障碍,建议在通用预防措施外增加有效预防传播、治疗即预防及快速转诊治疗并平衡肾移植候选资格。
要点
- 透析人群HCV高流行且血清阳转持续,微消除目标进展不足
- 障碍源于指南、法规与经济因素形成的复杂系统
- 需在通用预防外增加治疗即预防与快速转诊策略
核心结论
- 全球血液透析人群HCV传播持续,2030年微消除目标难以实现。
- 需设计更安全系统并整合预防、治疗即预防与快速转诊策略。
研究设计与样本
- 综述,检索范围未在摘要中报告。
主要发现
- 透析设施内HCV传播持续存在,全球HD患者HCV患病率仍高。
- 指南、立法、监管与经济因素交织构成消除障碍。
- 通用预防措施不足以阻断HCV传播。
临床怎么用
- 在通用预防基础上增加有效预防传播、治疗即预防与快速转诊治疗。
- 转诊治疗需与肾移植候选资格评估相平衡。
- 需设计更安全系统以阻断并消除透析人群HCV传播。
局限性
- 摘要未报告综述检索范围与纳入文献特征。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Chronic hepatitis C virus (HCV) infection continues to be transmitted to hemodialysis (HD) patients within HD facilities globally. The goal of the World Health Organization to micro-eliminate HCV infection from the HD population by the year 2030 is not on target to be achieved. Obstacles to eliminate HCV in HD settings remain daunting due to a complex system created by a confluence of guidelines, legislation, regulation, and economics. HCV prevalence remains high and seroconversion continues among the HD patient population globally as a result of the HD procedure. Preventive strategies that effectively prevent HCV transmission, treatment-as-prevention, and rapid referral to treatment balanced with kidney transplant candidacy should be added to the current universal precautions approach. A safer system must be designed before HCV transmission can be halted and eliminated from the HD population.
引用
- Rajasekaran A, Franco RA, Overton ET, et al. Updated Pathway to Micro-elimination of Hepatitis C Virus in the Hemodialysis Population. Kidney Int Rep. 2021. PMID: 34307975. doi:10.1016/j.ekir.2021.04.015
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。